Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.38 |
| ▸ | TOP1 | P11387 | 7/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL967926 | 0.90 | STAT3 (0.39) | STAT3TOP1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL964499 | 0.85 | STAT3 (0.52) | STAT3KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL967928 | 0.84 | KDM4E (0.46) | TOP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL12917147 | 0.83 | STAT3 (0.36) | STAT3TOP1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL9233680 | 0.81 | KDM4E (0.41) | STAT3TOP1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL1974491 | 0.79 | STAT3 (0.34) | STAT3TOP1KDM4EALDH1A1HPGD | |
| SCHEMBL12917038 | 0.78 | STAT3 (0.49) | STAT3KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL3869129 | 0.78 | TOP1 (0.45) | STAT3TOP1KMT2AKDM4EALDH1A1 | |
| SCHEMBL5118013 | 0.78 | STAT3 (0.33) | STAT3TOP1 | |
| SCHEMBL12917115 | 0.77 | KDM4E (0.45) | TOP1KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977349-B2 | Substituted quinolones III | AICURIS GMBH & CO. KG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7867992-B2 | such as 1-Cyclopropyl-N-(2,4-dichlorobenzyl)-6-fluoro-8-methoxy-7-[3-methyl-4-(2-{[(methylamino)carbonyl]amino}-2-oxoethyl)piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxamide, used for the treatment and/or prophylaxis of viral diseases or infections, particularly against cytomegaloviruses | AICURIS GMBH & CO. KG (DE) | 2011-01-11 | — | — | US | disclosed |
| US-7569563-B2 | Substituted quinolones II | AICURIS GMBH & CO. HK (DE) | 2009-08-04 | — | — | US | disclosed |
| US-20090181996-A1 | SUBSTITUTED QUINOLONES III | BAYER HEALTHCARE AG (DE) | 2009-07-16 | — | — | US | disclosed |
| US-20080261964-A1 | Substituted quinolones II | AICURIS GMBH & CO. KG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20070293478-A1 | Substituted quinolones | BAYER HEALTHCARE AG (DE) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181996-A1 | SUBSTITUTED QUINOLONES III | IRF3, TPMT, TOP2A | STAT3 3584/4885TOP1 4/4885SMN1; SMN2 3686/4885 |
| US-20080261964-A1 | Substituted quinolones II | TOP2A, TPMT, TOP2B | STAT3 4425/4885TOP1 4/4885SMN1; SMN2 3004/4885 |
| US-20070293478-A1 | Substituted quinolones | IRF3, TPMT, NQO2 | STAT3 3914/4885TOP1 8/4885SMN1; SMN2 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.